The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the ...

Double- or single-blinded randomised controlled trials (RCTs) comparing ketamine, memantine, esketamine or other glutamate receptor modulators with placebo (pill or saline infusion), other active ...

Memantine was developed from amantadine to increase the dwell time in the NMDA receptor channel. [25, 29] ...

The use of combination therapy with a cholinomimetic (AChEI) and a glutamatergic (memantine) agent for the treatment of AD is justified by findings from biochemical studies, and preclinical ...

Amplification of the human epidermal growth factor receptor 2 (HER2, Erb B2) gene leads to persistent activation of signaling pathways that enhance cell proliferation, resistance to apoptosis signals, ...

There are several neuropsychological theories about the pathology of schizophrenia, one of which is the glutamate theory. This theory suggests that hypofunction of NMDA receptors, which may be caused ...

Memantine selectively improves neural decoding of attended illusory contours, revealing NMDA receptor-dependent enhancement of feedback processing in human visual perception.

Recent findings have also identified anti-NMDA receptor autoantibodies in other neurological and psychiatric diseases such as schizophrenia, depression, bipolar disorder, and dementia.

Thus, G-protein-coupled receptors can regulate NMDA receptor function indirectly through a PKC-dependent activation of the non-receptor tyrosine kinase (Src) signaling cascade.

Recent findings have also identified anti-NMDA receptor autoantibodies in other neurological and psychiatric diseases such as schizophrenia, depression, bipolar disorder, and dementia. Arialys is ...

Arialys Therapeutics, a clinical-stage biotechnology company pioneering new precision medicines for autoimmune neuropsychiatric diseases, today announced the publication of preclinical data in Nature ...